Heather Preston, MD is an experienced healthcare venture capitalist and company builder with more than 30 years of industry experience. She currently serves as a Senior Advisor to TPG Biotech and sits on the Boards of Oxford Biomedica (OXB; LSE), Oxford Nanopore Technologies (ONT; LSE), Aligos Therapeutics (ALGS; Nasdaq), and Azura Ophthalmics. Previously, she was a Managing Partner of Pivotal Bioventures and a Firm Partner and Managing Director of TPG Biotech. Dr. Preston also held investing roles at JP Morgan Partners and New Enterprise Associates. Before her investing career, she spent five years at McKinsey & Co., where she led the pharmaceutical and medical products consulting practice. Dr. Preston holds an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. She completed a post-doctoral fellowship in molecular biology at the Dana-Farber Cancer Institute, Harvard University, and trained in Internal Medicine at Massachusetts General Hospital, and subspecialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she received a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship, and a Science and Engineering Research Council Post-Doctoral Fellowship Award.
